Wednesday, November 18, 2026
Noti Group
Business

Hims & Hers Launches Unapproved Peptide Treatments Platform

Hims & Hers Health is launching a new platform offering compounded peptide treatments that have become increasingly popular among fitness and longevity enthusiasts.

Hims & Hers launches new peptide treatments, while admitting there's more to learn about efficacy
Source: CNBC

Hims & Hers Health is launching a new platform offering compounded peptide treatments, which are not yet approved by regulators. The company's Peptides+ platform will initially include five formulations that have become increasingly popular among fitness and longevity enthusiasts.

These unapproved peptides, short chains of amino acids, have been touted as beneficial for muscle growth, rapid injury recovery, and anti-aging, despite a lack of robust human trials to support their claims. The federal government recently relaxed restrictions on compounding certain unapproved peptides, paving the way for companies like Hims & Hers to offer them.

Hims & Hers has acknowledged that there is still much to be learned about the effectiveness and optimal use of these peptides. This uncertainty underscores the challenges facing the industry as it navigates the growing demand for peptide treatments.

The company's new offerings have generated significant interest, with over 10,000 people signing up for early access within a short period of just 15 days. Hims & Hers has emphasized that its compounded products are authorized by law and formulated by pharmacies adhering to rigorous quality standards.

These pharmacies are licensed and inspected by state boards of pharmacy, ensuring compliance with regulatory requirements. The company's products include formulations of sermorelin, glutathione, nicotinamide adenine dinucleotide (NAD+), vitamin B-12, and L-carnitine.

While the FDA has approved certain prescription forms of these peptides for established medical uses, Hims & Hers' compounded versions are not yet cleared by regulators. The company's decision to offer unapproved peptide treatments has raised questions about the efficacy and safety of these products.

The launch of Hims & Hers' Peptides+ platform marks a significant step into the rapidly expanding market for peptide treatments, which have become increasingly popular among consumers seeking anti-aging and performance-enhancing benefits.

The company's plans for peptide treatments are not limited to its current offerings. In addition to BPC-157 and TB-500, Hims aims to introduce more peptides made in the U.S. over time.

These new additions will include BPC-157, a peptide derived from human gastric juice that is marketed for healing processes. However, most of the research on this peptide has been conducted in animals, not humans.

Another unapproved peptide set to be introduced by Hims is TB-500, which is naturally occurring and marketed for broader systemic recovery and flexibility. Again, much of the existing research on this peptide involves animal studies rather than human trials.

Before receiving peptide treatments, members of the Hims platform will undergo an assessment with a licensed provider trained in peptide therapies. This personalized plan takes into account their health history and goals.

As part of its support for patients, Hims plans to check in regularly through its communication platform to monitor progress and adjust treatment as needed. If results are not satisfactory, adjustments can be made or alternative compounds may be considered.

The company acknowledges that there is still much to be learned about the efficacy of these peptides in human subjects, with Dr. Anant Vinjamoori stating that they don't have all the data typically available for such treatments.

The new peptide treatments launched by Hims & Hers have sparked concerns among health experts about their safety and efficacy, particularly when it comes to serious illnesses.

People with conditions such as cardiovascular disease, liver disease, or kidney disease are currently not considered candidates for the compounds due to limited data on their effects in these cases.

Andrew Huberman, a neuroscientist and Stanford University School of Medicine professor who recently joined Hims' board of directors, emphasizes that peptides should be viewed as real medical treatments rather than just a wellness trend.

Experts caution against the mainstream marketing of peptides in the US, raising concerns about accessing them through telehealth platforms without proper testing or oversight.

Without rigorous clinical trials, researchers cannot rule out rare complications from peptide use, which could lead to regulatory issues similar to those faced by effective drugs that were later pulled from the market due to unforeseen risks.

The lack of established dosing guidelines for peptides also creates uncertainty among healthcare professionals and telehealth firms about what doses patients should take, potentially leading to adverse health effects.

Physicians who prescribe peptide treatments often have limited knowledge about their efficacy and safety due to a lack of established dosing guidelines.

The uncertainty surrounding peptide dosing creates challenges for both healthcare professionals and telehealth firms, which may lead to patients taking excessive or inadequate amounts of the peptides, potentially resulting in adverse health effects.

For patients using peptide and longevity products offered by Hims & Hers, the company provides access to its Care+ service, which offers ongoing support through twice-a-year lab testing and around-the-clock messaging with providers trained in peptide therapy.

However, some experts question whether telehealth platforms can provide sufficient supervision for patients taking prescription medications, especially unapproved peptides like those being offered by Hims & Hers.

A recent policy change by the Health and Human Services Department has allowed licensed pharmacies and physicians to compound and dispense six unapproved peptides without facing enforcement action from the FDA while formal rules are reviewed.

The policy shift permits these pharmacies and firms to offer the peptides, even though they have not been formally approved by the FDA, which maintains a list of ingredients that compounding pharmacies are authorized to make.

The FDA's restrictions on compounding pharmacies have been a topic of debate in recent years, particularly among advocates like HHS Secretary Robert F. Kennedy Jr., who has expressed support for broader access to peptides.

Kennedy, known for his enthusiasm towards peptide treatments, has personally used BPC-157 to treat a muscle injury and has spoken about its benefits. His stance on the matter is notable given the FDA's concerns over safety, impurity, and immune-reaction issues associated with certain peptide formulations.

The acquisition of a California-based peptide manufacturing facility by Hims in February 2025 marked an important milestone for the company, which can now utilize advanced peptide synthesizers to produce its treatments. This move has likely enhanced Hims' capabilities in developing and distributing peptides.

However, the evidence base supporting the efficacy of peptides is not yet robust, particularly when it comes to certain compounds. For instance, a 2026 systematic review found no eligible clinical outcome trials demonstrating the benefits of administering IV or intramuscular NAD+ in humans.

Some studies suggest that specific peptides may have beneficial effects, such as L-carnitine, which has been associated with weight loss. A review of 37 trials found participants lost an average of 2.7 pounds, although this analysis does not necessarily imply that compounded injections work the same way.

Research on vitamin B-12 injections is also limited to cases where people have a diagnosed deficiency, rather than preventive care. Interestingly, U.S. survey data reveals that only a small percentage, just 3.6% of adults, are deficient in vitamin B-12.

Reports of adverse events have been linked to glutathione injectable drugs sourced from a single wholesale distributor, which supplied dietary supplement grade ingredients not suitable for injectable use. This is according to the FDA, which received over 30 reports in August of patients experiencing problems after receiving compounded IV glutathione.

Two Texas pharmacies conducted recalls following discoveries of elevated endotoxin levels in their glutathione injectables. These findings underscore the existing knowledge gap regarding the efficacy and potential risks of these treatments, despite Hims' efforts to bring them to market. The exact performance of Hims' peptide combination remains uncertain due to limited data on its effects.

Facts based on reporting originally published by CNBC.

You may republish this story, in full or in part, if you credit Noti Group and link to it (licence CC BY 4.0). Photos are not included.